Stratagene Shares Dive 8.6 Percent After Judge Trebles Damages in Invitrogen IP-Infringement Verdict | GenomeWeb
NEW YORK (GenomeWeb News) — Shares in Stratagene were down 8.6 percent, or $.59, at $6.24 in mid-afternoon trading today after a judge ordered the company to pay $16 million in damages to Invitrogen for willfully infringing one of its patents.
 
Separately today, investment bank Robert W. Baird downgraded Stratagene’s stock to ‘Underperform’ from ‘Neutral.’
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Harold Varmus, a former NIH director, says that proposed reductions to the agency's budget are worrisome.

The Genome 10K project is to sequence about 10,000 vertebrate genomes, including ones of endangered species, Digital Trends reports.

The new Coalition to Save NIH Funding aims to educate lawmakers and the public on the significance of biomedical research.

In PLOS this week: analysis of viral sequences from human blood samples, gut microbiomes of heart failure patients, and more.